Gérard Zalcman
- Oncology top 0.5%
- Lung Cancer Research Studies 49
- Cancer Immunotherapy and Biomarkers 46
- Colorectal Cancer Treatments and Studies 19
- Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations 125
- Lung Cancer Diagnosis and Treatment 59
- Occupational and environmental lung diseases 43
- Pleural and Pulmonary Diseases 32
- Cancer Research top 2%
- Biotechnology top 1%
- Cancer Research and Treatments 19
- Immunology top 5%
Gérard Zalcman
275 papers receiving 6.6k citations
Hit Papers
Peers
Comparison fields: 5 of 135
- Oncology 3.5k
- Pulmonary and Respiratory Medicine 3.0k
- Cancer Research 890
- Biotechnology 342
- Immunology 678
Countries citing papers authored by Gérard Zalcman
This map shows the geographic impact of Gérard Zalcman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gérard Zalcman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gérard Zalcman more than expected).
Fields of papers citing papers by Gérard Zalcman
This network shows the impact of papers produced by Gérard Zalcman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gérard Zalcman. The network helps show where Gérard Zalcman may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Gérard Zalcman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 3 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 0 | |
| 5 | 2023 | 27 | |
| 6 | 2022 | 8 | |
| 7 | 2021 | 9 | |
| 8 | 2020 | 11 | |
| 9 | Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancerbreakdown → | 2020 | 554 |
| 10 | 2019 | 15 | |
| 11 | 2019 | 117 | |
| 12 | 2016 | 90 | |
| 13 | 2016 | 31 | |
| 14 | 2013 | 0 | |
| 15 | 2013 | 18 | |
| 16 | 2012 | 46 | |
| 17 | 2012 | 74 | |
| 18 | 2012 | 166 | |
| 19 | Quel traitement pour un patient de PS-2/3 ayant un cancer bronchique non à petites cellules (CBNPC) de stade IV ? | 2007 | 3 |
| 20 | 1999 | 5 |
About Gérard Zalcman
Gérard Zalcman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Biotechnology, having authored 299 papers that have together received 6.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (125 papers), Lung Cancer Diagnosis and Treatment (59 papers), Lung Cancer Research Studies (49 papers), Cancer Immunotherapy and Biomarkers (46 papers), Occupational and environmental lung diseases (43 papers), Pleural and Pulmonary Diseases (32 papers), Cancer Research and Treatments (19 papers) and Colorectal Cancer Treatments and Studies (19 papers). The work is most often cited by research in Oncology (3.5k citations), Pulmonary and Respiratory Medicine (3.0k citations) and Cancer Research (890 citations). Gérard Zalcman has collaborated with scholars based in France, United States and Italy. Frequent co-authors include B. Milleron, Franck Morin, Pierre-Jean Souquet, S. Couraud, Jean Trédaniel, Thierry Soussi, Emmanuel Bergot, Richard Lubin, Solenn Brosseau and V. Gounant. Their work appears in journals such as Journal of Biological Chemistry, Nature Medicine and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.